journal article·2023-06-07

Mitochondria-Targeting Pyroptosis Amplifier of Lonidamine-Modified Black Phosphorus Nanosheets for Glioblastoma Treatments

Youqing Ye, Ke Ren, Yuqin Dong, Lixin Yang, Dexin Zhang, Ziyang Yuan, Ningyi Ma, Yong Song, Xin Huang, Haishi Qiao

ACS Applied Materials & Interfaces· Volume 15· Issue 22
Publisher page

Abstract

Pyroptosis is accompanied by immunogenic mediators’ release and serves as an innovative strategy to reprogram tumor microenvironments. However, damaged mitochondria, the origin of pyroptosis, are frequently eliminated by mitophagy, which will severely impair pyroptosis-elicited immune activation. Herein, black phosphorus nanosheets (BP) are employed as a pyroptosis inducer delivery and mitophagy flux blocking system since the degradation of BP could impair lysosomal function by altering the pH within lysosomes. The pyroptosis inducer of lonidamine (LND) was precoupled with the mitochondrial target moiety of triphenylphosphonium to facilitate the occurrence of pyroptosis. The mitochondria-targeting LND-modified BP (BP TLD ) were further encapsulated into the macrophage membrane to endow the BP TLD with blood-brain barrier penetration and tumor-targeting capability. The antitumor activities of membrane-encapsulated BP TLD (M@BP TLD ) were investigated using a murine orthotopic glioblastoma model. The results demonstrated that the engineered nanosystem of M@BP TLD could target the mitochondria, and induce as well as reinforce pyroptosis via mitophagy flux blocking, thereby boosting the release of immune-activated factors to promote the maturation of dendritic cells. Furthermore, upon near-infrared (NIR) irradiation, M@BP TLD induced stronger mitochondrial oxidative stress, which further advanced robust immunogenic pyroptosis in glioblastoma cells. Thus, this study utilized the autophagy flux inhibition and phototherapy performance of BP to amplify LND-mediated pyroptosis, which might greatly contribute to the development of pyroptosis nanomodulators.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Inflammasome and immune disorders · Toxoplasma gondii Research Studies · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 210009, China

Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China

School of Laboratory Medicine/Sichuan Provincial Engineering Laboratory for Prevention and Control Technology of Veterinary Drug Residue in Animal-origin Food, Chengdu Medical College, Chengdu 610500, China

Funding

Jiangsu Province Postdoctoral Science Foundation · China Postdoctoral Science Foundation · Department of Science and Technology of Sichuan Province · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1016/j.tibs.2016.10.00410.1016/j.tibs.2016.10.004 ↗
2. 10.1038/nature2239310.1038/nature22393 ↗
3. 10.1038/s41573-021-00154-z10.1038/s41573-021-00154-z ↗
4. 10.1111/imr.1228710.1111/imr.12287 ↗
5. 10.1021/acsnano.2c0019210.1021/acsnano.2c00192 ↗
6. 10.1002/adma.20210672310.1002/adma.202106723 ↗
7. 10.1038/s41586-020-2071-910.1038/s41586-020-2071-9 ↗
8. 10.1038/s41422-018-0090-y10.1038/s41422-018-0090-y ↗
9. 10.1021/jacs.2c0325610.1021/jacs.2c03256 ↗
10. 10.1084/jem.2019054510.1084/jem.20190545 ↗
11. 10.1186/s13045-020-00985-010.1186/s13045-020-00985-0 ↗
12. 10.1038/s41586-020-2079-110.1038/s41586-020-2079-1 ↗
13. 10.1021/acs.nanolett.1c0279010.1021/acs.nanolett.1c02790 ↗
14. 10.1002/advs.20190284710.1002/advs.201902847 ↗
15. 10.1089/ars.2020.805810.1089/ars.2020.8058 ↗
16. 10.1016/j.trecan.2017.10.00610.1016/j.trecan.2017.10.006 ↗
17. 10.1016/j.cellsig.2022.11024710.1016/j.cellsig.2022.110247 ↗
18. 10.1016/j.cmet.2020.11.01810.1016/j.cmet.2020.11.018 ↗
19. 10.1038/sj.onc.120495310.1038/sj.onc.1204953 ↗
20. 10.1038/s41392-021-00524-410.1038/s41392-021-00524-4 ↗
21. 10.1021/acsami.1c0240410.1021/acsami.1c02404 ↗
22. 10.1021/acsami.7b1457710.1021/acsami.7b14577 ↗
23. 10.1038/s41467-019-10042-110.1038/s41467-019-10042-1 ↗
24. 10.1039/C8SC04844D10.1039/C8SC04844D ↗
25. 10.1002/advs.20200303310.1002/advs.202003033 ↗
26. 10.1007/s12274-021-3325-z10.1007/s12274-021-3325-z ↗
27. 10.1039/C8NR09368G10.1039/C8NR09368G ↗
28. 10.1002/anie.20181087810.1002/anie.201810878 ↗
29. 10.1016/j.matt.2019.12.00710.1016/j.matt.2019.12.007 ↗
30. 10.1016/j.ccr.2021.21411010.1016/j.ccr.2021.214110 ↗
31. 10.1002/adma.20160386410.1002/adma.201603864 ↗
32. 10.1021/acsnano.8b0737110.1021/acsnano.8b07371 ↗
33. 10.1007/s12274-021-3923-910.1007/s12274-021-3923-9 ↗
34. 10.1021/cb400944y10.1021/cb400944y ↗
35. 10.1016/j.jconrel.2022.03.05910.1016/j.jconrel.2022.03.059 ↗
36. 10.1016/j.cej.2021.13289810.1016/j.cej.2021.132898 ↗
37. 10.1021/acs.jmedchem.5b0116510.1021/acs.jmedchem.5b01165 ↗
38. 10.1039/D0CS01370F10.1039/D0CS01370F ↗
39. 10.1002/advs.20180051010.1002/advs.201800510 ↗
40. 10.1038/s41377-020-00388-310.1038/s41377-020-00388-3 ↗
41. 10.1126/sciadv.aay682510.1126/sciadv.aay6825 ↗
42. 10.1039/C7TB01068K10.1039/C7TB01068K ↗
43. 10.1021/acsnano.2c0089310.1021/acsnano.2c00893 ↗
44. 10.1002/adma.20160327610.1002/adma.201603276 ↗
45. 10.1016/j.jconrel.2019.01.02710.1016/j.jconrel.2019.01.027 ↗
46. 10.1016/j.bioactmat.2021.09.01610.1016/j.bioactmat.2021.09.016 ↗
47. 10.3390/ijms2208390310.3390/ijms22083903 ↗
48. 10.1002/adma.20170675910.1002/adma.201706759 ↗
49. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
50. 10.1021/acs.nanolett.7b0526310.1021/acs.nanolett.7b05263 ↗